To detect quinolone resistance-associated mutations within the Asp-86, Ser-87, Ser-88, and Glu-91 codons of the Neisseria gonorrhoeae parC gene, we developed a rapid and simple assay based on amplification of the regions of the parC gene containing the mutation sites by PCR and digestion of the PCR products with restriction enzymes. By using the method of primer-specified restriction site modification, artificial SalI, PstI, EcoRI, and HinfI restriction sites were created in the regions containing the Asp-86, Ser-87, Ser-88, and Glu-91 codons, respectively. The mutations generating alterations at Asp-86, Ser-87, Ser-88, and Glu-91 were detected as failures of SalI, PstI, EcoRI, and HinfI to digest the respective PCR products. Fifty-five clinical strains of N. gonorrhoeae were examined for mutations in the parC gene by this assay. Appropriate mutations at either the Asp-86, Ser-87, Ser-88, or Glu-91 codon were detected in each of 11 strains in which a mutation had previously been observed by DNA sequencing. This rapid and simple assay could be a useful device for screening genetic alterations in the parC gene associated with resistance to quinolones in N. gonorrhoeae.
Neisseria gonorrhoeae strains are susceptible to quinolones (12) , and selected quinolones are recommended as primary therapies for uncomplicated gonorrhea (3) . Recently, however, ciprofloxacin treatment failures associated with the development of resistance to the agent and clinical isolation of strains with decreased susceptibilities to fluoroquinolones have been reported (2, 4, 10, 13, 14, (17) (18) (19) . On the other hand, several mechanisms of quinolone resistance have been identified and characterized in N. gonorrhoeae strains with decreased susceptibilities to quinolones (1, 5, 6, 8, 15, 16) . Among the mechanisms analyzed so far, alteration of the GyrA subunit of DNA gyrase, particularly at Ser-91 and Asp-95, has a central role in conferring high-level quinolone resistance in N. gonorrhoeae (1, 8) . In addition, the alterations at Ser-88 and/or Gly-91 in the ParC subunit of DNA topoisomerase IV have been reported to be responsible for an increase in resistance to fluoroquinolones in laboratory mutant strains (1) . We have also reported that the alterations at Asp-86, Ser-87, Ser-88, and Gly-91 in ParC are associated with higher-level resistance to fluoroquinolones in clinical isolates (8) . These findings indicate that the alteration of ParC plays a complementary role in increasing resistance to fluoroquinolones. Therefore, to understand the mechanisms of quinolone resistance in N. gonorrhoeae, analysis of both the gyrA and parC genes is important and necessary. Although present technology allows for the reliable direct DNA sequencing of these genes without ligation, transformation, or other procedures (9) , this methodology is still labor-intensive and time-consuming. Thus, it is not suitable for the analysis of a large number of clinical strains, and simple and rapid assays are needed. We previously reported a rapid method for the detection of point mutations of the gyrA gene resulting in amino acid changes at Ser-91 and Asp-95 in clinical strains of N. gonorrhoeae (7) . The methodology of our assay involved the introduction of an artificial restriction enzyme cleavage site into the PCR product by use of a primer-specified restriction site modification method and restriction enzyme digestion of the PCR product (11). In the study described here, we applied this methodology to develop a method for the rapid screening of point mutations in the parC gene, thus generating quinolone resistance-associated amino acid changes in ParC of N. gonorrhoeae.
Bacteria. Fifty-five clinical strains of N. gonorrhoeae were used in this study. They had been examined for the presence of mutations in the gyrA and parC genes and tested for their susceptibilities to selected quinolones, including ciprofloxacin (6, 8) . These isolates consisted of 24 quinolone-susceptible strains (MICs of ciprofloxacin, 0.002 to 0.015 g/ml) and 31 strains with decreased susceptibilities to fluoroquinolones (MICs of ciprofloxacin, 0.06 to 8.0 g/ml). The quinolonesusceptible strains had no mutations in either the gyrA or the parC gene. Of the remaining 31 strains with decreased susceptibilities to fluoroquinolones, 20 strains had mutations in the gyrA gene alone, and 11 strains had mutations in both the gyrA and parC genes. The strains with mutations in both the gyrA and parC genes (MICs of ciprofloxacin, 0.25 to 8.0 g/ml) exhibited significantly higher levels of resistance to fluoroquinolones than did those with mutations in the gyrA gene alone (MICs of ciprofloxacin, 0.06 to 0.5 g/ml). Of these strains with mutations in the parC gene, six strains had a G-to-A change at nucleotide position 256 (Asp-863Asn), two strains had a G-to-T change at position 260 (Ser-873Ile), two other strains had a T-to-C change at position 262 (Ser883Pro), and one strain had an A-to-G change at position 271 (Glu-913Gly).
PCR and restriction enzyme digestion. The primers used in this study are presented in Table 1 . Primers NG-PARC-A and NG-PARC-B were described in our previous study (8) . The modified primers NG-PARC-SalI, NG-PARC-PstI, NG-PARC-EcoRI, and NG-PARC-HinfI were made adjacent to the mutation sites within the Asp-86, Ser-87, Ser-88, and Glu-91 codons with nucleotide sequences that differed by one or two bases from the gene sequence to create artificial SalI, PstI, EcoRI, and HinfI cleavage sites, respectively (Fig. 1) . Preparation of DNA from the strains, PCR amplification, and restriction enzyme digestion were performed as reported previously (7) . The digests of the PCR products were subjected to electrophoresis through 3% NuSieve 3:1 (FMC BioProduct, Rockland, Maine) agarose gels. The fragments in the gels were stained with ethidium bromide and were visualized with a UV transilluminator.
A total of 55 strains were analyzed by the assay. Figure 2 presents representative agarose gel electrophoresis profiles obtained by the assays. The DNA fragments amplified from the parC gene with primer sets were as follows: NG-PARC-SalI and NG-PARC-B, 132 bp; NG-PARC-PstI and NG-PARC-B, 123 bp; NG-PARC-EcoRI and NG-PARC-B, 118 bp; and NG-PARC-A and NG-PARC-HinfI, 103 bp. The PCR products amplified from the strains without mutations by using these primer pairs were digested with the appropriate enzyme. The PCR product amplified with NG-PARC-SalI and NG-PARC-B was digested with SalI to produce 28-and 104-bp fragments. The PCR product amplified with NG-PARC-PstI and NG-PARC-B was digested with PstI to produce 25-and 98-bp fragments. The PCR product amplified with NG-PARCEcoRI and NG-PARC-B was digested with EcoRI to produce 19-and 99-bp fragments. The PCR product amplified with NG-PARC-A and NG-PARC-HinfI was digested with HinfI to produce 76-and 27-bp fragments. The fragments of 104, 98, 99, and 76 bp were observed on the gels. However, the fragments of 28, 25, 19, and 27 bp which were theoretically produced by digestion with the respective restriction enzymes were not observed on the gels because they ran off the gels. In contrast, in the six strains with a G-to-A transition at nucleotide position 256 (Asp-863Asn), SalI failed to digest the PCR product amplified with NG-PARC-SalI and NG-PARC-B, and the 132-bp DNA fragment was observed. In the two strains with a G-to-T transition at nucleotide position 260 (Ser-873Ile), PstI did not digest the PCR product amplified with NG-PARC-PstI and NG-PARC-B, and the 123-bp DNA fragment was observed. In the two strains with a G-to-T transition at nucleotide position 262 (Ser-883Pro), EcoRI did not cut the PCR product amplified with NG-PARC-EcoRI and NG-PARC-B, and the 118-bp DNA fragment was observed. In the strain with an A-to-G transition at nucleotide position 271 (Glu-913Gly), HinfI did not cut the PCR product amplified with NG-PARC-A and NG-PARC-HinfI, and the 103-bp DNA fragment was observed. These DNA fragments had the same sizes as their original PCR products. Overall, appropriate mutations at either the Asp-86, Ser-87, Ser-88, or Glu-91 codon were detected by this assay in each of 11 strains in which a mutation had previously been observed by DNA sequencing (8) . Thus, the validity of this assay for the detection of point mutations in the N. gonorrhoeae parC gene associated with resistance to quinolones was confirmed.
This assay requires neither radioisotopes nor equipment other than that necessary to perform PCR and agarose gel electrophoresis, and it requires minimal training. In addition, it allows for the simultaneous testing of a large number of strains. However, this assay has several limitations, including the inability to predict what nucleotide transposition is present in the parC gene and an inability to screen mutations occurring at other nucleotide positions of the gene. Until recently, no studies have reported quinolone resistance-associated mutations of the parC gene in laboratory or clinical strains of N. gonorrhoeae that are not detectable by the assay described here. Therefore, our assay could screen the majority of the mutations in the   FIG. 1 . PCR products into which restriction enzyme cleavage sites were introduced by using the primer-specified restriction site modification method. When DNA fragments were amplified from a wild-type parC gene by PCR, the modified primers (boxed areas) of NG-PARC-SalI (A), NG-PARC-PstI (B), NG-PARC-EcoRI (C), and NG-PARC-HinfI (D) create artificial SalI, PstI, EcoRI, and HinfI cleavage sites (underlined), respectively, in the regions containing the positions (denoted by asterisks), at which nucleotide changes are observed in quinolone-resistant laboratory and clinical strains of N. gonorrhoeae (1, 8) , within the Asp-86, Ser-87, Ser-88, and Glu-91 codons. Lowercase letters indicate the bases that are different from those in the wild-type N. gonorrhoeae parC gene. parC gene that are likely to occur commonly in quinoloneresistant N. gonorrhoeae strains.
In conclusion, the rapid, simple assay described here could be a relevant tool for assessing whether genetic alterations in the parC gene associated with quinolone resistance are present in N. gonorrhoeae strains. This assay, together with the assay that we previously developed for the gyrA gene (7), would help provide an understanding of the mechanisms of quinolone resistance in N. gonorrhoeae and a means of carrying out epidemiological assessments of the transmission and spread of strains with decreased susceptibilities to quinolones.
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